Glaxosmithkline | GSK - Pre Tax Profit



Glaxosmithkline reported $1.89B in Pre-Tax Profit for its fiscal quarter ending in June of 2025.


Pre Tax Profit Change Date
AbbVie USD 1.66B 3.15B Mar/2025
Amgen USD 1.57B 405M Jun/2025
AstraZeneca USD 3.13B 275M Jun/2025
Aurora Cannabis CAD -19380000 51.45M Jun/2025
Bausch Health Companies USD 140M 187M Jun/2025
Bristol-Myers Squibb USD 1.77B 1.2B Jun/2025
Canopy Growth CAD -41240000 80.34M Jun/2025
Corcept Therapeutics USD 31.69M 22.07M Jun/2025
Drreddys Laboratories 19.05B 304M Jun/2025
Eli Lilly USD 6.78B 3.32B Jun/2025
GlaxoSmithKline GBP 1.89B 221M Jun/2025
Glaxosmithkline USD 1.89B 230.76M Jun/2025
J&J USD 13.63B 8.21B Mar/2025
Merck USD 6.77B 864M Jun/2025
Novartis USD 4.53B 124M Jun/2025
Pacira USD -1927000 10.63M Jun/2025
Perrigo USD 3.2M 5.1M Jun/2025
Pfizer USD 3.04B 259M Jun/2025
Prestige Brands USD 61.78M 12.18M Jun/2025
Roche Holding CHF 1.78B 2.33B Dec/2024
Sanofi EUR 1.42B 734M Jun/2025
Supernus Pharmaceuticals USD 16.67M 22.5M Jun/2025
Takeda JPY 150.63B 257.93B Jun/2025
Teva Pharmaceutical Industries USD 203M 91M Jun/2025
Zoetis USD 902M 92M Jun/2025